Look back at pharma news in the week to April 24, 2020

26 April 2020

By Barbara Obstoj-Cardwell. Editor

Regulatory news last week included two important decisions from the US Food and Drug Administration. First up, Seattle Genetics gained FDA approval for its breast cancer candidate Tukysa (tucatinib). The other was FDA clearance for Incyte’s Pemazyre (pemigatinib) as a treatment for metastatic cholangiocarcinoma. Clinical trial news of note included Switzerland-based Idorsia scoring a goal with positive Phase III results with its investigational insomnia treatment daridorexant, and AstraZeneca on Friday presented new data on its Lynparza in the treatment of prostate cancer.

Early Tukysa approval, broad label exceeds expectations

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK